XML 16 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating expenses:    
Research and development $ 11,951,023 $ 13,305,306
General and administrative 6,267,412 9,682,554
Total operating expenses 18,218,435 22,987,860
Loss from operations (18,218,435) (22,987,860)
Other income:    
Interest/investment income, net 440,287 1,055,888
Realized gain on short-term investments 62,952 53,133
Unrealized gain on short-term investments 155,731 50,713
Total other income 658,970 1,159,734
Net loss $ (17,559,465) $ (21,828,126)
Loss per common share – basic (in Dollars per share) $ (0.58) $ (0.72)
Loss per common share – diluted (in Dollars per share) $ (0.58) $ (0.72)
Weighted average number of common shares outstanding – basic (in Shares) 30,408,890 30,132,170
Weighted average number of common shares outstanding – diluted (in Shares) 30,408,890 30,132,170